Should I buy or sell Eli Lilly and Company stock right now?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares. View LLY analyst ratings or view top-rated stocks .

What is Eli Lilly and Company's stock price target for 2024?

19 analysts have issued 1 year price objectives for Eli Lilly and Company's stock. Their LLY share price targets range from $500.00 to $1,001.00. On average, they expect the company's stock price to reach $787.53 in the next year. This suggests that the stock has a possible downside of 11.7%. View analysts price targets for LLY or view top-rated stocks among Wall Street analysts .

How have LLY shares performed in 2024?

Eli Lilly and Company's stock was trading at $582.92 at the beginning of the year. Since then, LLY stock has increased by 52.9% and is now trading at $891.46. View the best growth stocks for 2024 here .

When is Eli Lilly and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our LLY earnings forecast .

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) announced its earnings results on Monday, May, 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The company earned $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 56.98% and a net margin of 17.08%. The firm's revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter last year, the business posted $1.62 earnings per share. Read the conference call transcript .

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company declared a quarterly dividend on Monday, May 6th. Shareholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share on Monday, June 10th. This represents a $5.20 annualized dividend and a yield of 0.58%. The ex-dividend date of this dividend is Wednesday, May 15th. Read our dividend analysis for LLY .

Is Eli Lilly and Company a good dividend stock?

Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $5.20 per share and currently has a dividend yield of 0.59%. The dividend payout ratio is 76.58%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, LLY will have a dividend payout ratio of 26.97% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for LLY .

What ETFs hold Eli Lilly and Company's stock?

ETFs with the largest weight of Eli Lilly and Company (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE) , Horizon Kinetics Medical ETF (MEDX) , Amplify Weight Loss Drug & Treatment ETF (THNR) , iShares U.S. Healthcare ETF (IYH) , VanEck Pharmaceutical ETF (PPH) , Health Care Select Sector SPDR Fund (XLV) , Goldman Sachs Future Health Care Equity ETF (GDOC) and Fidelity MSCI Health Care Index ETF (FHLC) .

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of 13.500-14.000 for the period, compared to the consensus estimate of 12.500. The company issued revenue guidance of $42.4 billion-$43.6 billion, compared to the consensus revenue estimate of $41.4 billion.

What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com . David A. Ricks has an approval rating of 86% among the company's employees.

What other stocks do shareholders of Eli Lilly and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ) , Pfizer (PFE) , NVIDIA (NVDA) , Intel (INTC) , Cisco Systems (CSCO) , Bristol-Myers Squibb (BMY) , Walt Disney (DIS) , AT&T (T) , Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM) .

Who are Eli Lilly and Company's major shareholders?

Eli Lilly and Company's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.65%), Capital World Investors (2.58%), Price T Rowe Associates Inc. MD (2.17%), Capital Research Global Investors (0.85%), Jennison Associates LLC (0.79%) and Capital International Investors (0.73%). Insiders that own company stock include Acquisition Corp Kearny, Alonzo Weems , Anne E White , Donald A Zakrowski , Ilya Yuffa , Jackson P Tai , Johna Norton , Lilly Endowment Inc, Marschall S Runge and Patrik Jonsson. View institutional ownership trends .

How do I buy shares of Eli Lilly and Company?

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Eli Lilly and Company have any subsidiaries?

The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos. Read More

NYSE:LLY

Eli Lilly and Company (LLY) Stock Price, News & Analysis

→ The asset beating inflation by 4x (From Colonial Metals) (Ad)

Free LLY Stock Alerts

$891.46

+6.45 (+0.73%)

(As of 06/18/2024 ET)

Compare

Today's Range: $884.00
▼
$894.87
50-Day Range: $724.87
▼
$891.46
52-Week Range: $434.34
▼
$894.87

Volume: 2.41 million shs
Average Volume: 2.94 million shs
Market Capitalization: $847.25 billion

P/E Ratio: 131.29
Dividend Yield: 0.58%
Price Target: $787.53

Get Eli Lilly and Company alerts:

Eli Lilly and Company MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.84 Rating Score
Upside/Downside: 11.7% Downside
$787.53 Price Target
Short Interest: Healthy
0.72% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -2.25
Upright™ Environmental Score
News Sentiment: 0.71
Based on 48 Articles This Week
Insider Trading: Selling Shares
$648.11 M Sold Last Quarter
Proj. Earnings Growth: 40.12%
From $13.76 to $19.28 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.56 out of 5 stars

Medical Sector

79th out of 913 stocks

Pharmaceutical Preparations Industry

27th out of 430 stocks

2.4

Analyst's Opinion

Consensus Rating
Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on 16 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Eli Lilly and Company has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Eli Lilly and Company's stock forecast and price target.

3.0

Short Interest

Percentage of Shares Shorted
0.72% of the float of Eli Lilly and Company has been sold short.
Short Interest Ratio / Days to Cover
Eli Lilly and Company has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eli Lilly and Company has recently increased by 14.07%, indicating that investor sentiment is decreasing significantly.

0.8

Dividend Strength

Dividend Yield
Eli Lilly and Company has a dividend yield of 0.59%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Eli Lilly and Company does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Eli Lilly and Company is 76.58%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 26.97% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.
Read more about Eli Lilly and Company's dividend.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eli Lilly and Company has received a 56.49% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Peptide analogs", "Pemetrexed", "Insulin", and "SGLT2 inhibitors" products. See details.
Environmental Sustainability
The Environmental Impact score for Eli Lilly and Company is -2.25.

2.6

News and Social Media Coverage

News Sentiment
Eli Lilly and Company has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 48 news articles for Eli Lilly and Company this week, compared to 37 articles on an average week.
Search Interest
125 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.
MarketBeat Follows
Only 68 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $648,109,138.00 in company stock.
Percentage Held by Insiders
Only 0.13% of the stock of Eli Lilly and Company is held by insiders.
Percentage Held by Institutions
82.53% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Eli Lilly and Company's insider trading history.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly and Company are expected to grow by 40.12% in the coming year, from $13.76 to $19.28 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly and Company is 131.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.39.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly and Company is 131.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 178.31.
Price to Earnings Growth Ratio
Eli Lilly and Company has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly and Company has a P/B Ratio of 77.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Eli Lilly and Company's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

[Urgent] Protect your money before November

Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.

Click here to watch now.

About Eli Lilly and Company Stock (NYSE:LLY)

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

Written by Jeffrey Neal Johnson

LLY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LLY Stock News Headlines

June 19 at 5:28 AM | insidertrades.com

Eli Lilly and Company (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 194,978 Shares

June 18 at 7:15 AM | marketbeat.com

3 Strong Buy Stocks for a Sizzling Summer Rally

After last week's data dump of inflation readings and the Federal Reserve's latest decision to hold interest rates steady, investors can take a deep breath before the next earnings season kicks off in just a few weeks.

June 19, 2024 | InvestorPlace (Ad)

Must-See: Elon’s New Invention is Absolutely Insane

Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.

June 18 at 7:15 AM | marketbeat.com

3 Strong Buy Stocks for a Sizzling Summer Rally (LLY)

Investors can take a deep breath before the next earnings season, but they should still invest in equities, including these three gems hiding in plain sight

June 18 at 4:22 AM | insidertrades.com

Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells $13,256,464.34 in Stock

June 12, 2024 | insidertrades.com

Eli Lilly and Company (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 75,510 Shares

June 11, 2024 | insidertrades.com

Insider Selling: Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells 139,490 Shares of Stock

June 7, 2024 | insidertrades.com

Lilly Endowment Inc Sells 20,383 Shares of Eli Lilly and Company (NYSE:LLY) Stock

June 19, 2024 | InvestorPlace (Ad)

Must-See: Elon’s New Invention is Absolutely Insane

Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.

June 5, 2024 | insidertrades.com

Insider Selling: Eli Lilly and Company (NYSE:LLY) Major Shareholder Sells 192,794 Shares of Stock

June 4, 2024 | insidertrades.com

Eli Lilly and Company (NYSE:LLY) CAO Sells $614,602.50 in Stock

June 4, 2024 | insidertrades.com

Insider Selling: Eli Lilly and Company (NYSE:LLY) EVP Sells 7,056 Shares of Stock

June 19 at 4:36 AM | fool.com

Eli Lilly Stock Analysis: Buy, Hold, or Sell?

June 19 at 1:46 AM | americanbankingnews.com

Cantor Fitzgerald Reiterates "Overweight" Rating for Eli Lilly and Company (NYSE:LLY)

June 17 at 10:01 PM | marketwatch.com

Broadcom passes Eli Lilly to become 8th largest U.S. company by market cap

June 17 at 5:58 PM | seekingalpha.com

Eli Lilly And Alzheimer's Disease: The Paucity Of Progress

June 17 at 12:32 PM | barrons.com

Broadcom Is on Track to Edge Past Eli Lilly's Market Value. AI Is Helping It Do So.

June 17 at 9:00 AM | cnbc.com

How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi

June 16 at 12:05 PM | fool.com

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

June 15, 2024 | fool.com

Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?

June 15, 2024 | fool.com

Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster

June 15, 2024 | fool.com

3 Growth Stocks You Can Buy Right Now Without Any Hesitation

June 15, 2024 | investorplace.com

Exit Alert: 3 Stocks to Offload Before the Downturn

June 15, 2024 | americanbankingnews.com

Eli Lilly and Company (NYSE:LLY) Given Average Rating of "Moderate Buy" by Analysts

June 14, 2024 | 247wallst.com

10 Reasons to Buy Eli Lilly Stock Now

June 14, 2024 | gurufocus.com

From Sci-Fi Dream to Market Maze: Eli Lilly's Weight-Loss Medications Face Hurdles

June 14, 2024 | fool.com

Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug

See More Headlines

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/06/2024
Ex-Dividend for 6/10 Dividend: 5/15/2024
Dividend Payable: 6/10/2024
Today: 6/18/2024
Next Earnings (Estimated): 8/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NYSE:LLY
CUSIP: 53245710
CIK: 59478
Web: www.lilly.com
Phone: (317) 276-2000
Fax: 317-276-4878
Employees: 43,000
Year Founded: 1876

Price Target and Rating

Average Stock Price Target: $787.53
High Stock Price Target: $1,001.00
Low Stock Price Target: $500.00
Potential Upside/Downside: -11.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.84
Research Coverage: 19 Analysts

Profitability

EPS (Most Recent Fiscal Year): $6.79
Trailing P/E Ratio: 131.29
Forward P/E Ratio: 64.79
P/E Growth: 1.92
Net Income: $5.24 billion
Net Margins: 17.08%
Pretax Margin: 21.04%
Return on Equity: 56.98%
Return on Assets: 10.94%

Debt

Debt-to-Equity Ratio: 1.90
Current Ratio: 1.35
Quick Ratio: 1.03

Sales & Book Value

Annual Sales: $34.12 billion
Price / Sales: 24.83
Cash Flow: $7.74 per share
Price / Cash Flow: 115.18
Book Value: $11.44 per share
Price / Book: 77.92

Miscellaneous

Outstanding Shares: 950,410,000
Free Float: 949,169,000
Market Cap: $847.25 billion
Optionable: Optionable
Beta: 0.36

Social Links

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. David A. Ricks (Age 56)
Chairman, CEO & President
Comp: $6.29M
Ms. Anat Ashkenazi (Age 51)
Executive VP & CFO
Comp: $2.96M
Dr. Daniel M. Skovronsky M.D. (Age 50)
Ph.D., EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Comp: $3.82M
Ms. Anat Hakim J.D. (Age 55)
Executive VP, General Counsel & Secretary
Comp: $2.81M
Mr. Jacob S. Van Naarden (Age 39)
Executive VP & President of Loxo
Comp: $2.38M
Mr. Donald A. Zakrowski
Senior VP of Finance & Chief Accounting Officer
Mr. Diogo Rau (Age 49)
EVP & Chief Information and Digital Officer
Comp: $1.06M
Mr. Alonzo Weems (Age 52)
EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer
Mr. Eric Dozier (Age 56)
Executive Vice President of Human Resources & Diversity
Mr. Jeffrey N. Simmons (Age 57)
Senior VP & President of Elanco Animal Health
Comp: $1.73M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

Eli Lilly and Company's stock price has been consistently increasing, reaching $865.74 on June 11, 2024, indicating positive market sentiment.
The company reported strong earnings results, with earnings per share of $2.58 for the last quarter, surpassing the consensus estimate by $0.05.
Eli Lilly and Company has a high return on equity of 56.98%, showcasing efficient utilization of shareholder funds to generate profits.
The company pays a quarterly dividend of $1.30 per share, providing investors with a steady income stream and a yield of 0.62%.
Eli Lilly and Company has a diverse portfolio of pharmaceutical products with a focus on innovation and global market presence, reducing dependency on a single product or market.

Cons

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

Despite the positive aspects, Eli Lilly and Company's stock has a high price-to-earnings ratio of 126.74, which may indicate an overvalued stock compared to industry peers.
The company's price-to-earnings-growth ratio of 1.85 suggests that the stock may be relatively expensive in terms of its growth prospects.
Eli Lilly and Company's beta of 0.36 indicates low volatility compared to the market, potentially limiting short-term trading opportunities for investors seeking higher returns.
The debt-to-equity ratio of 1.90 may raise concerns about the company's financial leverage and ability to manage debt obligations effectively.
Large insider selling activities, such as Lilly Endowment Inc selling significant shares, could signal lack of confidence in the company's future performance among major stakeholders.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, June 11, 2024. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

LLY Stock Analysis - Frequently Asked Questions

Should I buy or sell Eli Lilly and Company stock right now?: 19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.
What is Eli Lilly and Company's stock price target for 2024?: 19 analysts have issued 1 year price objectives for Eli Lilly and Company's stock. Their LLY share price targets range from $500.00 to $1,001.00. On average, they expect the company's stock price to reach $787.53 in the next year. This suggests that the stock has a possible downside of 11.7%.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.
How have LLY shares performed in 2024?: Eli Lilly and Company's stock was trading at $582.92 at the beginning of the year. Since then, LLY stock has increased by 52.9% and is now trading at $891.46.
View the best growth stocks for 2024 here.
When is Eli Lilly and Company's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our LLY earnings forecast.
How were Eli Lilly and Company's earnings last quarter?: Eli Lilly and Company (NYSE:LLY) announced its earnings results on Monday, May, 6th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. The company earned $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 56.98% and a net margin of 17.08%. The firm's revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter last year, the business posted $1.62 earnings per share.
Read the conference call transcript.
How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?: Eli Lilly and Company declared a quarterly dividend on Monday, May 6th. Shareholders of record on Thursday, May 16th will be paid a dividend of $1.30 per share on Monday, June 10th. This represents a $5.20 annualized dividend and a yield of 0.58%. The ex-dividend date of this dividend is Wednesday, May 15th.
Read our dividend analysis for LLY.
Is Eli Lilly and Company a good dividend stock?: Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $5.20 per share and currently has a dividend yield of 0.59%. The dividend payout ratio is 76.58%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, LLY will have a dividend payout ratio of 26.97% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.
What ETFs hold Eli Lilly and Company's stock?: ETFs with the largest weight of Eli Lilly and Company (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Horizon Kinetics Medical ETF (MEDX), Amplify Weight Loss Drug & Treatment ETF (THNR), iShares U.S. Healthcare ETF (IYH), VanEck Pharmaceutical ETF (PPH), Health Care Select Sector SPDR Fund (XLV), Goldman Sachs Future Health Care Equity ETF (GDOC) and Fidelity MSCI Health Care Index ETF (FHLC).

What guidance has Eli Lilly and Company issued on next quarter's earnings?: Eli Lilly and Company updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share (EPS) guidance of 13.500-14.000 for the period, compared to the consensus estimate of 12.500. The company issued revenue guidance of $42.4 billion-$43.6 billion, compared to the consensus revenue estimate of $41.4 billion.
What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?: 399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.
What other stocks do shareholders of Eli Lilly and Company own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).
Who are Eli Lilly and Company's major shareholders?: Eli Lilly and Company's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.65%), Capital World Investors (2.58%), Price T Rowe Associates Inc. MD (2.17%), Capital Research Global Investors (0.85%), Jennison Associates LLC (0.79%) and Capital International Investors (0.73%). Insiders that own company stock include Acquisition Corp Kearny, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Johna Norton, Lilly Endowment Inc, Marschall S Runge and Patrik Jonsson.
View institutional ownership trends.
How do I buy shares of Eli Lilly and Company?: Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Eli Lilly and Company have any subsidiaries?: The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More

This page (NYSE:LLY) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Eli Lilly and Company (LLY) Stock Price, News & Analysis

Eli Lilly and Company MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Dividend Coverage

Dividend Sustainability

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Earnings Growth Ratio

Price to Book Value per Share Ratio

About Eli Lilly and Company Stock (NYSE:LLY)

LLY Stock Price History

LLY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

Pros

Cons

LLY Stock Analysis - Frequently Asked Questions

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Overall MarketRank^™